文献速递肝病消化道出血

弗赖堡TIPS术后生存指数(FIPS)可识别TIPS术后进一步失代偿和慢加急性肝衰竭风险患者

Freiburg index of post-TIPS survival (FIPS) identifies patients at risk of further decompensation and ACLF after TIPS.
PubMed 文献 · J Hepatol · 2025-02-04

本研究回顾性纳入8家三级中心的1359例接受TIPS的肝硬化患者,按FIPS分层分析术后临床病程。FIPS高危患者TIPS术后90天内进一步失代偿和ACLF发生率显著更高,且两者均与无移植生存率降低相关,FIPS高危可独立预测上述事件。

要点

  • FIPS高危患者TIPS术后90天内进一步失代偿累积发生率0.58,高于低危患者的0.38(p<0.001)。
  • FIPS高危患者TIPS术后90天内ACLF累积发生率0.18,高于低危患者的0.08(p=0.008)。
  • FIPS高危独立预测进一步失代偿(sHR 1.974)和ACLF(sHR 2.586),两者均与无移植生存率降低相关。

核心结论

  • FIPS可预测TIPS术后进一步失代偿和ACLF的发生,这些事件是FIPS高危患者无移植生存率受损的原因。

研究设计与样本

  • 回顾性纳入8家三级中心的1359例肝硬化患者,因复发性或难治性腹水或食管胃静脉曲张出血二级预防接受TIPS。
  • 按FIPS对患者TIPS术后临床病程进行分层分析。

主要发现

  • TIPS术后进一步失代偿在FIPS高危患者中比低危患者更常见(累积发生率函数0.58 vs 0.38,p<0.001)。
  • FIPS高危患者ACLF发生更频繁(0.18 vs 0.08;p=0.008)。
  • 多因素竞争风险回归显示,FIPS高危独立预测进一步失代偿(亚分布风险比1.974;95%CI 1.531-2.544;p<0.001)。
  • FIPS高危独立预测ACLF(亚分布风险比2.586;95%CI 1.449-4.616;p=0.001)。
  • TIPS术后进一步失代偿和ACLF与无移植生存率显著降低相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The Freiburg index of post-TIPS survival (FIPS) defines a high-risk group of patients with significantly reduced survival following transjugular intrahepatic portosystemic shunt (TIPS) implantation. However, the clinical hallmarks responsible for these patients' unfavorable outcome remain to be identified. Therefore, the present study aimed to characterize the clinical course after TIPS implantation according to the FIPS. METHODS: A total of 1,359 patients with cirrhosis allocated to TIPS implantation for treatment of recurrent or refractory ascites or secondary prophylaxis of variceal bleeding from eight tertiary centers were retrospectively included. The patients' clinical course following TIPS placement was analyzed, stratified according to the FIPS. The primary study outcome was further decompensation within 90 days after TIPS; secondary outcomes were acute-on-chronic liver failure (ACLF) within 90 days and 1-year transplant-free survival. RESULTS: Further decompensation after TIPS implantation was significantly more frequent in FIPS high-risk patients compared to low-risk patients (cumulative incidence function 0.58 vs. 0.38, p <0.001). Moreover, FIPS high-risk patients developed ACLF significantly more often (0.18 vs. 0.08; p = 0.008). Uni- and multivariable competing risk regression analyses confirmed that high-risk FIPS independently predicted further decompensation (subdistribution hazard ratio 1.974; 95% CI 1.531-2.544; p <0.001) and ACLF (subdistribution hazard ratio 2.586; 95% CI 1.449-4.616; p = 0.001) after TIPS. Importantly, further decompensation and ACLF after TIPS were associated with significantly reduced transplant-free survival. CONCLUSIONS: The present study reveals that the FIPS predicts development of further decompensation and ACLF after TIPS implantation. These events are responsible for impaired transplant-free survival in FIPS high-risk patients. These results pave the way for the development of tailored clinical management strategies. IMPACT AND IMPLICATIONS: Prognostication after transjugular intrahepatic portosystemic shunt (TIPS) implantation is challenging. Several clinical scores have been proposed in this context, such as the Freiburg index of post-TIPS survival (FIPS). The FIPS can identify a high-risk group of patients with significantly reduced survival after TIPS. However, to understand the reasons for these patients' unfavorable outcome, their clinical course after TIPS needs to be characterized. This study reveals that the FIPS predicts development of further decompensation and acute-on-chronic liver failure after TIPS implantation, which are responsible for the poor prognosis of FIPS high-risk patients. Therefore, the present results may be useful for tailored decision making in patients allocated to TIPS implantation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sturm L, Schultheiss M, Stöhr F, et al. Freiburg index of post-TIPS survival (FIPS) identifies patients at risk of further decompensation and ACLF after TIPS. J Hepatol. 2025. PMID: 39914747. doi:10.1016/j.jhep.2025.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。